|
|
The first patient and many others received no international attention until February 2003, when a physician from Guangdong Province became ill while staying on the ninth floor of a hotel in Hong Kong. Twelve guests became infected, including at least seven who stayed in rooms on the ninth floor. These hotel guests subsequently became the index patients who transported the disease to Vietnam, Singapore, Canada, Ireland, and the United States. As of April 17, there had been 3389 cases and 165 deaths (a death rate of 4.9 percent) reported in 27 countries.
As reported in this issue of the Journal, microbiologic data from large groups at the Centers for Disease Control and Prevention (CDC) (pages 1953–1966) and in Europe (pages 1967–1976) strongly suggest that a novel coronavirus is the causative agent. Both teams isolated the virus in Vero-cell cultures, showed significant antibody responses in patients, and identified a unique coronavirus by gene sequencing. The European team found high concentrations of coronavirus RNA in sputum and low concentrations in plasma and feces from patients. The typical crown-like structure of coronavirus was identified at the CDC by electron microscopy of infected culture cells. Poutanen et al. (pages 1995–2005) isolated the new coronavirus in respiratory specimens from five of nine patients in Canada. Experimental studies have recently shown that the virus can infect primates, causing SARS.
Coronaviruses are ubiquitous and cause illness in many animals, including pigs, cattle, dogs, cats, and chickens. They have been associated with upper respiratory infections and sometimes pneumonia in humans. Genetic changes occur frequently, and the proximity of humans to animals in southern China may have caused a recombinant animal virus to become an accidental tourist, crossing species to humans in Guangdong Province, leading to an epidemic among highly mobile and susceptible populations globally.
Although large-droplet transmission seems to be important in the spread of SARS, implying a requirement for intimate contact with a patient, the unusually rapid transmission suggests that airborne transmission through droplet nuclei (<10 µm in diameter) can occur. Such droplet nuclei, which are key in the transmission of influenza, measles, and tuberculosis, allow the organisms to reach directly the alveoli of the lungs of contacts. Alternatively, viral contamination of the water supply or fomites might be important in some locales.
From the perspective of clinicians, all cases of community-acquired pneumonia are currently suspect, and a history of exposure to a patient with probable SARS increases the likelihood of the diagnosis. Suggestive laboratory features, as described by Lee at al. (pages 1986–1994), include lymphopenia, thrombocytopenia, and elevated lactate dehydrogenase levels. In patients with suspected SARS, a workup for known causes of community-acquired pneumonia should be performed, and specimens should be sent to the CDC for viral identification and serologic analysis (see Table).
|
Most physicians have prescribed standard antibacterial regimens for community-acquired pneumonia, and some have added a neuraminidase inhibitor to cover both influenzavirus A and influenzavirus B. Until we have a predictive test for the causative agent of SARS, this approach is reasonable. Supplementary oxygen should be administered if the patient has hypoxemia. The antiviral drug ribavirin has been used extensively to treat SARS, but there are no data to show that it is effective. Intravenous administration was used in the patients who were most ill, and oral administration (resulting in bioavailability of approximately 50 percent) was used in other patients. In order to use the intravenous form, a clinician in the United States must contact the CDC Emergency Operations Center (770-488-7100). Health Canada recently stated, however, that it will no longer provide access to ribavirin for the treatment of SARS, because of concern about its side effects and lack of in vitro efficacy.
Some physicians have also prescribed corticosteroids for patients with severe cases. A rationale for the use of corticosteroids derives from the pathological findings suggestive of cytokine dysregulation and hyperinduction of inflammatory mediators with diffuse alveolar damage. In the report by Lee et al., computed tomographic studies of the chest showed bilateral peripheral changes with ground-glass consolidation similar to that seen in bronchiolitis obliterans with organizing pneumonia. The latter is an inflammatory disease involving both terminal bronchioles and alveoli that usually responds to corticosteroids. In this time of uncertainty, we favor the use of corticosteroids only for the more ill patients. Because injectable methylprednisolone and hydrocortisone are currently in short supply in the United States, the options are oral formulations or intravenous dexamethasone.
SARS has created international anxiety because of its novelty, communicability, and rapid spread through jet travel and because it has caused illness in a large proportion of exposed medical and nursing personnel. We simply do not know where we are on the epidemic curve. Some fear is rational, but the 4.9 percent mortality rate is in fact similar to that seen generally with community-acquired pneumonia in the United States. Furthermore, the total number of deaths remains a small fraction of the estimated 35,000 deaths from influenza each year in the United States alone.
As the epidemic unfolds, praise is due to the hundreds of health care workers throughout the world who come to work every day to assist patients with SARS despite some risks to their own health. Such dedication defines the best traditions of our profession.
Source Information
From the Department of Internal Medicine, Virginia Commonwealth University, Richmond.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Letters:
Managing SARS
Bouadma L., Noël V., Schortgen F., Donohue C., Wenzel R. P., Edmond M. B.
Extract |
Full Text |
PDF
N Engl J Med 2003;
349:707-708, Aug 14, 2003.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |
